Bristol-Myers offloads $1.4B in pension risk; GSK partners with GE on melanoma diagnostics;

@FiercePharma: Report: Indian government to take legal action over drug quality paper. FiercePharmaManufacturing item | Follow @FiercePharma

@TracyStaton: ICYMI: Who are the fiercest companies in biotech these days? Check out @FierceBiotech's latest Fierce 15. Special Report | Follow @TracyStaton

@CarlyHFierce: Pfizer DTC message: Hey guys, women say it's cool to take Viagra. Story via FiercePharmaMarketing | Follow @CarlyHFierce

> Bristol-Myers Squibb ($BMY) transferred $1.4 billion in pension liabilities to Prudential Financial, cutting its pension obligations to $3.6 billion. Report

> GlaxoSmithKline ($GSK) is teaming up with GE Healthcare ($GE) to boost diagnostic testing in cancer patients to help individualize treatment; the tests will initially focus on mutations in melanoma, including two targeted by GSK meds. Release

> Pharma's European trade group says it didn't lobby for a controversial change to the governance over drugs in the EU. Report

> The FDA rejected a petition to force drug companies to reformulate drugs such as Adderall, Ritalin and painkillers to prevent abuse. Report

> Walgreen's ($WAG) U.S. drug business fueled record sales, thanks to increasing numbers of Medicare patients. Report

Medical Device News

@FierceMedDev: We've compiled the 15 fiercest med tech companies. Check out FierceMedicalDevices' Fierce 15. Special Report | Follow @FierceMedDev

@MichaelGFierce: RT @EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. Report from FierceBiotechResearch | Follow @MichaelGFierce

@VarunSaxena2: Med tech attorneys say FDA ramping up monitoring of device promotion. Editor's Corner | Follow @VarunSaxena2

@EmilyWFierce: Babies tune out sounds that don't exist in mother's native tongue, form "library of sounds" in brain. Story from Wired | Follow @EmilyWFierce

> Endo to settle remaining claims over vaginal mesh products. Article

> Developer of eye test for Alzheimer's raises $15M in VC round. News

Biotech News

@FierceBiotech: Hemispherx to test FDA-rejected drug, other candidates against Ebola. FierceBiotech Research story | Follow @FierceBiotech

@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). More | Follow @JohnCFierce

@DamianFierce: And now the @FierceMedDev Fierce 15, featuring therapeutic apps, next-gen valves and a light-based hearing aid. Report from FierceMedicalDevices | Follow @DamianFierce

@EmilyMFierce: Global Survey Says We're Eating Better, But Our Diet Is Still Unsustainable. National Geographic story | Follow @EmilyMFierce

> Novartis drops out of hep C race, punting a $440M Enanta pact. More

> FibroGen lines up a $125M IPO to shoulder its way into the IPF race. Story

> AstraZeneca partner Ardelyx scores a trial success for GI drug. News

> Portola's 'breakthrough' anti-anticoagulant clears a Phase III hurdle. Article

Drug Delivery News

> Projection: Implantable drug delivery market to reach $21.1B by 2018. Item

> Which vehicle works best? High-speed testing gives drug delivery a boost. Story

> Alnylam launches study to support its rare disease candidate ALN-AS1. More

> Allergan's drug-delivering eye implant gets expanded indication from FDA. News

> Detoxified anthrax used to deliver cancer drugs within cells. Article

Diagnostics News

> Thermo Fisher has made universal companion Dx development an official trend. Report

> Autism diagnosis could become clearer with sound/sight response screening. More

> Japan approves Infraredx's intravascular ultrasound Dx imaging device. Article

> Trinity Biotech expects FDA submission in early 2015 for heart failure Dx. Story

> J&J, others join $6.5M funding round for U.K. liquid biopsy company. Item

Pharma Marketing News

> Pfizer DTC message: Hey guys, women say it's cool to take Viagra. Story

> Survey: No need to worry about sky-high prices for orphan drugs. Item

> Sunshine fact: $3.5B + 546,000 docs equals one unwieldy database. Report

> Sucampo's Amitiza targets 45-plus women with belly-as-balloon DTC ads. Article

And Finally... Sanofi ($SNY) opened the doors on its first research hub in Asia, located in Shanghai, China. Report

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.